Tom Stinchcombe

28PUBLICATIONS

134CO-AUTHORS

Molecular targetsEpidemiological modellingCancer therapy (excl. chemotherapy and radiation therapy)Solid tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (28)

Sort by Publication Date:

|Jul 03, 2026

Alirocumab Plus Cemiplimab in Immunorefractory NSCLC: A Single Arm Phase 2 Study.

|Jan 21, 2026

Prevalence and Clinical Characteristics of Germline Epidermal Growth Factor Receptor Mutations in the Southeastern Unites States.

Jenny O'Brien, Ryne C Ramaker, Ashley Moyer

|Jan 13, 2026

Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005.

Kristin A Higgins, Chen Hu, Helen J Ross

|Oct 30, 2025

Multi-Institution Analysis of Tarlatamab for the Treatment of <i>EGFR</i>-Mutant Transformed Small Cell Lung Cancer.

Alissa J Cooper, Benjamin Herzberg, Mitchell Parma

|Oct 23, 2025

A Phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancer.

Hirva Mamdani, Ryan D Gentzler, Lin Gu

|Aug 11, 2025

Milademetan in Advanced Solid Tumors with MDM2 Amplification and Wild-type TP53: Preclinical and Phase II Clinical Trial Results.

Ecaterina E Dumbrava, Thomas E Stinchcombe, Mrinal Gounder

Pageof 5

Frequent Collaborators

Jeffrey D Bradley

Suresh S Ramalingam

Robert G Maki

Tanios Bekaii-Saab

Gini F Fleming

Danny Nguyen

Yoshiaki Nakamura

Nobumasa Mizuno

Yu Sunakawa

Erika P Hamilton

Frequent Collaborators

Jeffrey D Bradley

Suresh S Ramalingam

Robert G Maki

Tanios Bekaii-Saab